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The human embryonic stem cell line RCe012-A (RC-8) was derived from a frozen and thawed day 5 embryo cultivated to the blastocyst stage. The embryo was voluntarily donated as unsuitable and surplus to fertility requirements following ethics committee approved informed consent under licence from the UK Human Fertilisation and Embryology Authority. The cell line shows normal pluripotency marker expression and differentiation to the three germ layers in vitro. It has a normal 46XX female karyotype and microsatellite PCR identity, HLA and blood group typing data is available.
© 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Resource table

Resource details
RCe012-A (RC-8) was derived from a thawed day 5 blastocyst that was surplus to requirement or unsuitable for clinical use. The cell line was derived by whole embryo outgrowth on mitotically inactivated human fibroblast (HDF) feeder cells using xeno-free medium (XF KODMEM) and expanded under xeno free and feeder free conditions. By flow cytometry, RCe012-A (RC-8) expressed the pluripotency makers Oct-4, Tra-1-60 and SSEA-4 (94.7%, 89.4% and 99.8%, respectively), whereas low expression of the differentiation marker SSEA-1 (2.2%) was observed ( Fig. 1 , Table 1 ). Differentiation to the three germ layers, endoderm, ectoderm and mesoderm, was demonstrated using embryoid body formation and expression of the germ layer markers αfetoprotein, β-tubulin and muscle actin (Fig. 2) .
A microsatellite PCR profile has been obtained for the cell line, and HLA Class I and II typing is available (Table 2 ). Blood group genotyping gave the blood group AO 1 (Table 2) .
Verification and authentication
The cell line was analysed for genome stability by G-banding ( Fig. 3 ) and showed a normal 46XX female genotype. The cell line is free from mycoplasma contamination as determined by RC-qPCR. Microsatellite PCR DNA profiling for cell identity is available (Table 2) .
Materials and methods
Ethics
Derivation of hESC from surplus to requirement and failed to fertilise/develop embryos was approved by The Scotland A Research Ethics Committee and local ethics board at participating fertility clinics and conducted under licence no R0136 from the UK HFEA with informed donor consent. 
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Cell culture
Vitrified embryos were thawed using Vitrified Embryo Safety Thawing Pack (Kitazato/Dibimed, Valencia, Spain) according to manufacturers' instruction and were cultured in system SAGE Quinn's Advanced Blastocyst medium (Rochford Medical, Coventry) after day 3 of development. Embryos were cultured at 36.5-37.5°C, 5 ± 0.5% CO 2 , 5 ± 0.5% O 2 in drops under paraffin oil (Rochford Medical) and transferred to fresh medium at least every 2-3 days.
By day 8 of development, embryos were placed in derivation conditions consisting of mitotically inactivated neonatal human dermal fibroblasts (HDFs) (ThermoFisher Scientific (Cascade Biologics), Paisley, UK) on tissue culture plastic in XF KODMEM medium (Knockout-DMEM, 15% KOSR-XF, 2 mM L-glutamine, 1% MEM Non-essential amino acids, 2% XF Growth Factor Cocktail, 0.1 mM β-mercaptoethanol, all ThermoFisher Scientific, Paisley, UK) supplemented with 80 ng/ml human bFGF (ThermoFisher Scientific). Assisted hatching was performed by removing the zona pellucidae mechanically using Swemed Cutting tools (Vitrolife, Göteborg, Sweden).
HDF cells were cultured in DMEM (Lonza, Slough, UK), 10% FCS (GE Healthcare (PAA), Buckinghamshire, UK) and 2 mM L-glutamine (ThermoFisher Scientific). HDFs were mitotically inactivated using gamma irradiation at 50GY using a Gammacell Elite 1000 machine. For use as a feeder layer, irradiated HDFs were plated at 50,000 cells/ cm 2 in XF KODMEM medium supplemented with 80 ng/ml human bFGF (ThermoFisher Scientific). Cells were cultured at 36.5-37.5°C, 5 ± 0.5% CO 2 , 5 ± 0.5% O 2 and 50% medium exchanged 6 days a week.
The established cell line was expanded and banked using CellStart matrix and Stempro hESC Serum Free Medium (ThermoFisher Scientific). Passaging was performed mechanically using an EZ passage tool (ThermoFisher Scientific). hESC lines were expanded to 25-30 wells of a 6-well plate and cryopreserved in 0.5-1 ml Cryostor CS10 (Biolife Solution, Washington, USA).
Mycoplasma
Mycoplasma detection was performed using Applied Biosystems PrepSEQ™ Mycoplasma Nucleic Acid Extraction Kit and MicroSEQ™ Mycoplasma Real-Time PCR Detection Kit (ThermoFisher Scientific (Applied Biosystems)) according to manufacturer's instruction.
Endotoxin
Endotoxin levels were determined using the Kinetic-QCL assay (Lonza) and an incubating plate reader (BioTek ELx808) according to manufacturer's instructions. Briefly, an unknown sample was compared with a standard curve of known levels of control endotoxin. An assay was deemed valid if the coefficient of correlation, r ≥ 0.980 and the CV (%) for the standard curve was ≤10%. Fig. 1 . RCe012-A (RC-8) was subjected to flow cytometry analysis for markers of pluripotency with specific antibody (top row) or isotype control (bottom row) as indicated above the histograms. Percentage staining is indicated in Table 1 . 
Flow cytometry
Pluripotency was determined using the Human and Mouse Pluripotent Stem Cell Analysis kit (BD, Oxford, UK). Oct 3/4 and SSEA-4 were included as pluripotency markers, and SSEA-1 as a differentiation marker. FITC conjugated Tra-1-60 (BD) was used as an additional pluripotency marker. Fixed and permeabilised cells were analysed using a FACS Aria flow cytometer (BD). Percentage expression of each marker was compared to isotype control or unstained cells.
Immunocytochemistry hESC were fixed in methanol (ThermoFisher Scientific), blocked using 10% goat serum (Sigma-Aldrich, Dorset, UK) in PBS (Lonza) containing 0.01% Tween-20 (Sigma) and stained with AFP (1:500; Sigma), βtubulin III (1:1000; Sigma), muscle-specific actin (1:50; DAKO, Glostrup, Denmark), and secondary antibody anti-goat IgG-AlexaFluor 488 (1:200; ThermoFisher Scientific). Images were acquired using a Zeiss S100 Axiovert fluorescence microscope or Nikon eC1 confocal microscope.
In vitro differentiation
Confluent hESC cells lifted using a cell scraper (Corning) and embryoid bodies EBs generated in ultra low attachment plates (Corning) in EB medium (20% FBS (GE Healthcare (PAA)), 80% KO-DMEM 1 mM L-glutamine, 0.1 mM β-mercaptoethanol, 1% nonessential amino acids (all ThermoFisher Scientific)). After 9 days in suspension culture, EBs were being transferred onto glass slide tissue culture chambers (Nunc, ThermoFisher Scientific) coated with 0.1% gelatin (Sigma) at 0.1 ml/cm 2 and cultured for 14 days.
Genomic analysis
All outsourced assays were carried out under a Quality and Technical Agreement. DNA was extracted using the QIAamp DNA Mini kit (Qiagen, Manchester, UK) according to manufacturer's recommendations and provided in recommended quantities to the service providers.
Microsatellite PCR, or Short Tandem Repeat analysis, was used to determine cell line identity and was carried out by Public Health England. A profile was obtained for the following core alleles: vWA, D16S539, Amelogenin, THO1, CSF1PO, D5S818, D75820, D135317 and TPOX.
Human Leukocyte Antigen (HLA) tissue typing was carried out by the Scottish National Blood Transfusion Service.
Blood group genotyping was carried out by the Molecular Diagnostics laboratory at NHSBT.
Karyotype analysis was carried out by The Doctors Laboratory (London, UK) or the Western General Cytogenetics Laboratory (Edinburgh, UK) Live cells at 60-70% confluency were shipped overnight in warm containers, fixed and analysed by standard G-banding analysis. For research grade lines, 20 spreads were analysed. HLA tissue typing HLA class I type HLA-A*02, A*32; B*15, B*38; C*03, C*12 HLA class II type HLA-DRB1*04, DRB1*15; DRB4*01; DRB5*01; DQB1*06, DQB1*03 Comment C*03 is expressed serologically as C10, B*15 is expressed serologically as B62, DQB1*03 is expressed serologically as a DQ8. 
